A Phase 1 Comparative Pharmacokinetic and Cardiac Safety Study of Two Intravenous Formulations of CO-101 in Patients With Advanced Solid Tumors

F. E. Stuurman*, Martijn P. Lolkema, Alwin D. R. Huitema, P. M. M. B. Soetekouw, Hilde Rosing, L. Rolfe, P. Kaur, Jos H. Beijnen, H. van Tinteren, E.E. Voest, Jan H. M. Schellens

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

10 Citations (Web of Science)
Original languageEnglish
Pages (from-to)878-883
JournalJournal of Clinical Pharmacology
Volume53
Issue number8
DOIs
Publication statusPublished - Aug 2013

Keywords

  • gemcitabine
  • CO-101
  • CP-4126
  • bioequivalence
  • QT
  • QTc intervals
  • dFdC
  • dFdU
  • phase 1
  • lipid
  • phospholipids
  • cancer
  • formulation
  • infusion

Cite this